Renan C. Castillo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Renan C. Castillo has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Robert V. O'TOole
Department of Orthopaedics, University of Maryland School of Medicine, Baltimore, Maryland
10 shared publications Metrc
Department of Orthopedic Surgery, University of Washington Medicine—Harborview Medical Center, Seattle, WA
9 shared publications- Nathan N. O'HAra
Department of Orthopaedic Surgery, University of California, Irvine, Irvine, CA
7 shared publications - Anthony R. Carlini
Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
6 shared publications - Katherine P. Frey
Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
6 shared publications - Joshua L. Gary
Keck School of Medicine of the University of Southern California, Los Angeles, California
5 shared publications
Latest Publications
- Open Access
- 1 March 2026
- Published by Wolters Kluwer Health in OTA International
- Vol. 9 (1)
Treatment of high-energy lower extremity trauma is explained by the Orthopaedic Trauma Association Open Fracture Classification
Objectives: To examine the association of Orthopaedic Trauma Association Open Fracture Classification (AO FC-OFC) designation for a specific high-energy lower extremity fracture with the need for 3 or more surgeries, soft -tissue closure with a flap, or amputation. Design: Secondary analysis of multicenter prospective observational study. Setting: Thirty-two Level 1 trauma centers. Patient/Participants: Adult patients admitted from July 2012 to October 2015 with open pilon, ankle, talus, calcaneus, foot crush, or blast injuries. Main Outcome Measurements: Multivariable regression analyses examined the association between the OTA-FC (contamination, bone loss, muscle, skin and arterial injury) with 3 or more trips to the OR before definitive fixation, soft-tissue closure with a flap, and amputation within 18 months of injury. Results: A total of 447 patients comprised the study population. In adjusted models, embedded contamination [odds ratio (OR) = 3.0, 95% confidence interval (CI): 1.54–5.99], functional muscle loss (OR = 2.6, 95% CI: 1.60–4.23), skin that cannot be approximated (OR = 10.0, 95% CI: 5.02–19.79), and degloving (OR = 5.9, 95% CI: 2.94–11.61) were significantly associated with 3+ OR trips. Embedded contamination (OR = 2.2, 95% CI: 1.00–4.86), skin that cannot be approximated (OR = 23.8, 95% CI: 11.73–48.12), and degloving (OR = 12.4, 95% CI: 5.87–26.05) were significantly associated with soft tissue closure with a flap. Dead muscle (OR = 12.9, 95% CI: 4.78–34.89), arterial injury with ischemia (OR = 12.0, 95% CI: 3.22–44.27), skin that cannot be approximated (OR = 2.4, 95% CI: 1.03–5.37), and degloving (OR = 3.0, 95% CI: 1.25–6.98) were significantly associated with amputation. Conclusions: The OTA-FC variables that were most important for predicting treatment intervention varied. The severity of skin injury was associated with all outcomes.
- 1 March 2026
- Published by Wolters Kluwer Health in OTA International
- Vol. 9 (1)
Open AccessTreatment of high-energy lower extremity trauma is explained by the Orthopaedic Trauma Association Open Fracture Classification
Objectives: To examine the association of Orthopaedic Trauma Association Open Fracture Classification (AO FC-OFC) designation for a specific high-energy lower extremity fracture with the need for 3 or more surgeries, soft -tissue closure with a flap, or amputation. Design: Secondary analysis of multicenter prospective observational study. Setting: Thirty-two Level 1 trauma centers. Patient/Participants: Adult patients admitted from July 2012 to October 2015 with open pilon, ankle, talus, calcaneus, foot crush, or blast injuries. Main Outcome Measurements: Multivariable regression analyses examined the association between the OTA-FC (contamination, bone loss, muscle, skin and arterial injury) with 3 or more trips to the OR before definitive fixation, soft-tissue closure with a flap, and amputation within 18 months of injury. Results: A total of 447 patients comprised the study population. In adjusted models, embedded contamination [odds ratio (OR) = 3.0, 95% confidence interval (CI): 1.54–5.99], functional muscle loss (OR = 2.6, 95% CI: 1.60–4.23), skin that cannot be approximated (OR = 10.0, 95% CI: 5.02–19.79), and degloving (OR = 5.9, 95% CI: 2.94–11.61) were significantly associated with 3+ OR trips. Embedded contamination (OR = 2.2, 95% CI: 1.00–4.86), skin that cannot be approximated (OR = 23.8, 95% CI: 11.73–48.12), and degloving (OR = 12.4, 95% CI: 5.87–26.05) were significantly associated with soft tissue closure with a flap. Dead muscle (OR = 12.9, 95% CI: 4.78–34.89), arterial injury with ischemia (OR = 12.0, 95% CI: 3.22–44.27), skin that cannot be approximated (OR = 2.4, 95% CI: 1.03–5.37), and degloving (OR = 3.0, 95% CI: 1.25–6.98) were significantly associated with amputation. Conclusions: The OTA-FC variables that were most important for predicting treatment intervention varied. The severity of skin injury was associated with all outcomes.
- Open Access
- 20 February 2026
- Published by Wolters Kluwer Health in OTA International
- Vol. 9 (1)
Effect of nonsteroidal anti-inflammatory drugs on union, opioid utilization, and pain management for tibial fractures (NSAID Trial): a pragmatic randomized clinical trial protocol
Objectives: The orthopaedic community has largely avoided the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of pain after fractures based on a combination of animal and clinical data, which suggest their association with impeded fracture healing. Given the significant deleterious effects of opiate analgesics, the use of NSAIDs for pain management in fracture care would be advantageous if potential concerns related to bone healing could be resolved. This study is designed to determine whether planned use of scheduled NSAIDs after fracture leads to a difference in fracture union rates, which in turn provides evidence regarding whether prohibition of NSAID use is justified. Design: This was a prospective, two-arm, pragmatic, randomized-controlled multicenter Phase III noninferiority trial. Setting: The study was conducted at 14 Level I trauma centers across the United States and Canada. Patients: Patients aged 18 to 80 years with open (Gustilo Type I, II, or IIIA) or closed tibia fractures treated with intramedullary nailing were included. Intervention: Patients received 600 milligrams of ibuprofen, 3 times daily, for up to 6 weeks. Main Outcome Measurements: Secondary surgery to achieve union within 12 months of definitive fixation was recorded.
- 20 February 2026
- Published by Wolters Kluwer Health in OTA International
- Vol. 9 (1)
Open AccessEffect of nonsteroidal anti-inflammatory drugs on union, opioid utilization, and pain management for tibial fractures (NSAID Trial): a pragmatic randomized clinical trial protocol
Objectives: The orthopaedic community has largely avoided the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the management of pain after fractures based on a combination of animal and clinical data, which suggest their association with impeded fracture healing. Given the significant deleterious effects of opiate analgesics, the use of NSAIDs for pain management in fracture care would be advantageous if potential concerns related to bone healing could be resolved. This study is designed to determine whether planned use of scheduled NSAIDs after fracture leads to a difference in fracture union rates, which in turn provides evidence regarding whether prohibition of NSAID use is justified. Design: This was a prospective, two-arm, pragmatic, randomized-controlled multicenter Phase III noninferiority trial. Setting: The study was conducted at 14 Level I trauma centers across the United States and Canada. Patients: Patients aged 18 to 80 years with open (Gustilo Type I, II, or IIIA) or closed tibia fractures treated with intramedullary nailing were included. Intervention: Patients received 600 milligrams of ibuprofen, 3 times daily, for up to 6 weeks. Main Outcome Measurements: Secondary surgery to achieve union within 12 months of definitive fixation was recorded.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (1)
Thrombelastography as a Predictive Tool for Thromboembolic Events After Extremity Trauma
Background: Venous thromboembolism (VTE) poses significant risk of morbidity and mortality in orthopaedic trauma patients. Thromboelastography (TEG) analysis has been demonstrated to provide value in demonstrating hypercoagulability and predicting the risk of post-injury VTE. The primary aim was to investigate if TEG analysis at the time of admission following severe extremity trauma predicts thromboembolic events. We hypothesized that previously described elevations in maximal amplitude (MA) on initial TEG would correlate with an increased risk of VTE. Methods: This was a secondary study of PREVENT CLOT, a multicenter, randomized trial that enrolled adult patients with an extremity fracture (from hip to midfoot or shoulder to wrist) treated operatively or any pelvic or acetabular fracture. TEG at admission was performed according to local protocols. The primary outcome of this analysis was postoperative VTE. We assessed the association between admission TEG values and VTE using bivariate and multivariable regression analyses. Statistical significance was set at p < 0.05. Results: Thousand one hundred eighty-three patients enrolled participants in the PREVENTion of CLots in Orthopedic Trauma (PREVENT CLOT) trial had TEG analysis performed on initial presentation. Of these patients, 47 (3.97%) had a symptomatic postoperative VTE at a median of 9 days (interquartile range, 4-18 days). There were no differences in VTE rates when examining MA of ≥65, ≥69, or ≥72 (p = 0.12, 0.21, and 0.19, respectively). However, on admission TEG, reaction time (R-time) was significantly higher among those who experienced a postoperative deep venous thrombosis (2.45 vs. 1.79, p < 0.01). After controlling for confounders, R-time of ≥2.0 was associated with a 2.1-fold increased odds of VTE (OR 2.13, 95% confidence interval 1.06-4.28, p < 0.001). Conclusion: In contrast to previous smaller retrospective studies, elevated admission-TEG MA values were not predictive of VTE following operative orthopaedic extremity trauma in this secondary analysis of a large multicenter prospective study. Our findings suggest that an increased R-time on the admission TEG, which is thought to be indicative of a longer time to form a clot, may be paradoxically associated with an increased VTE risk in orthopedic trauma patients. Level of Evidence: Level II . See Instructions for Authors for a complete description of levels of evidence.
- 1 January 2026
- Published by Wolters Kluwer Health in JBJS Open Access
- Vol. 11 (1)
Open AccessThrombelastography as a Predictive Tool for Thromboembolic Events After Extremity Trauma
Background: Venous thromboembolism (VTE) poses significant risk of morbidity and mortality in orthopaedic trauma patients. Thromboelastography (TEG) analysis has been demonstrated to provide value in demonstrating hypercoagulability and predicting the risk of post-injury VTE. The primary aim was to investigate if TEG analysis at the time of admission following severe extremity trauma predicts thromboembolic events. We hypothesized that previously described elevations in maximal amplitude (MA) on initial TEG would correlate with an increased risk of VTE. Methods: This was a secondary study of PREVENT CLOT, a multicenter, randomized trial that enrolled adult patients with an extremity fracture (from hip to midfoot or shoulder to wrist) treated operatively or any pelvic or acetabular fracture. TEG at admission was performed according to local protocols. The primary outcome of this analysis was postoperative VTE. We assessed the association between admission TEG values and VTE using bivariate and multivariable regression analyses. Statistical significance was set at p < 0.05. Results: Thousand one hundred eighty-three patients enrolled participants in the PREVENTion of CLots in Orthopedic Trauma (PREVENT CLOT) trial had TEG analysis performed on initial presentation. Of these patients, 47 (3.97%) had a symptomatic postoperative VTE at a median of 9 days (interquartile range, 4-18 days). There were no differences in VTE rates when examining MA of ≥65, ≥69, or ≥72 (p = 0.12, 0.21, and 0.19, respectively). However, on admission TEG, reaction time (R-time) was significantly higher among those who experienced a postoperative deep venous thrombosis (2.45 vs. 1.79, p < 0.01). After controlling for confounders, R-time of ≥2.0 was associated with a 2.1-fold increased odds of VTE (OR 2.13, 95% confidence interval 1.06-4.28, p < 0.001). Conclusion: In contrast to previous smaller retrospective studies, elevated admission-TEG MA values were not predictive of VTE following operative orthopaedic extremity trauma in this secondary analysis of a large multicenter prospective study. Our findings suggest that an increased R-time on the admission TEG, which is thought to be indicative of a longer time to form a clot, may be paradoxically associated with an increased VTE risk in orthopedic trauma patients. Level of Evidence: Level II . See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 40 (1) , 22-29
Effect of Aspirin Versus Low-Molecular-Weight Heparin for Thromboprophylaxis in High-Risk and Fracture Location Subpopulations: A Secondary Analysis of the PREVENT CLOT Trial
OBJECTIVES: To compare the effectiveness and safety of aspirin versus low-molecular-weight heparin (LMWH) for thromboprophylaxis in 11 high-risk or fracture location subpopulations. METHODS: Design: A post hoc secondary analysis of the published PREVENT CLOT trial. Setting: 21 trauma centers. Patient Selection Criteria: Adult patients with an operatively treated extremity fracture or any pelvic or acetabular fracture were enrolled from April 2017 through August 2021. Patients with only hand or foot fractures, presenting >48 hours after injury, or with a history of venous thromboembolism within 6 months of injury were excluded. The 11 subpopulations included (1) head injury, (2) abdominal injury, (3) spinal injury, (4) thoracic injury, (5) multiply injured patients, (6) obesity, (7) previous venous thromboembolism ≥6 months, (8) isolated upper extremity fracture, (9) isolated lower extremity fracture, (10) isolated pelvic or acetabular fracture, and (11) geriatric femur fracture. Outcome Measures and Comparisons: The primary outcome was 90-day all-cause mortality. Secondary outcomes included nonfatal pulmonary embolism, proximal deep vein thrombosis (DVT), distal DVT, and bleeding events. Outcomes were assessed using Kaplan–Meier estimators and Cox proportional hazards models comparing 81 mg of aspirin versus 30 mg of LMWH twice daily. The threshold for statistical significance was a Bonferroni-corrected alpha of 0.001 to account for multiple comparisons. RESULTS: The largest subpopulations were isolated lower extremity fractures (n = 6289), obesity (n = 4234), and polytrauma with Injury Severity Score (ISS) >16 (n = 1596). No comparison of aspirin versus LMWH within the 11 subpopulations for the 5 outcomes reached the corrected threshold for statistical significance of P < 0.001. However, 5 comparisons of aspirin versus LMWH were less than the conventional P -value of 0.05. Specifically, the aspirin group demonstrated lower mortality in patients with a head injury (difference, −3.2%; 95% CI −6.1% to −0.3%; P = 0.03) or a spine injury (difference, −6.0%; 95% CI −11.7% to −0.3%; P = 0.04) than the LMWH group. The LMWH group demonstrated a lower rate of distal DVTs for patients with a head injury (difference, 4.4%; 95% CI, 0.8% to 8.1%; P = 0.02), thoracic injury (difference, 1.5%; 95% CI, 0.0% to 2.9%; P = 0.04) or with ISS >16 (difference, 1.7%; 95% CI, 0.2% to 3.3; P = 0.03) than the aspirin group. CONCLUSIONS: Within 11 high-risk or fracture location-specific subpopulations, there were no statistically significant differences between aspirin and LMWH in the 90-day rates of all-cause mortality, nonfatal PE, proximal DVT, distal DVT, or bleeding complications at a threshold corrected for multiple comparisons ( P < 0.001). LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
- 1 January 2026
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 40 (1) , 22-29
Open AccessEffect of Aspirin Versus Low-Molecular-Weight Heparin for Thromboprophylaxis in High-Risk and Fracture Location Subpopulations: A Secondary Analysis of the PREVENT CLOT Trial
OBJECTIVES: To compare the effectiveness and safety of aspirin versus low-molecular-weight heparin (LMWH) for thromboprophylaxis in 11 high-risk or fracture location subpopulations. METHODS: Design: A post hoc secondary analysis of the published PREVENT CLOT trial. Setting: 21 trauma centers. Patient Selection Criteria: Adult patients with an operatively treated extremity fracture or any pelvic or acetabular fracture were enrolled from April 2017 through August 2021. Patients with only hand or foot fractures, presenting >48 hours after injury, or with a history of venous thromboembolism within 6 months of injury were excluded. The 11 subpopulations included (1) head injury, (2) abdominal injury, (3) spinal injury, (4) thoracic injury, (5) multiply injured patients, (6) obesity, (7) previous venous thromboembolism ≥6 months, (8) isolated upper extremity fracture, (9) isolated lower extremity fracture, (10) isolated pelvic or acetabular fracture, and (11) geriatric femur fracture. Outcome Measures and Comparisons: The primary outcome was 90-day all-cause mortality. Secondary outcomes included nonfatal pulmonary embolism, proximal deep vein thrombosis (DVT), distal DVT, and bleeding events. Outcomes were assessed using Kaplan–Meier estimators and Cox proportional hazards models comparing 81 mg of aspirin versus 30 mg of LMWH twice daily. The threshold for statistical significance was a Bonferroni-corrected alpha of 0.001 to account for multiple comparisons. RESULTS: The largest subpopulations were isolated lower extremity fractures (n = 6289), obesity (n = 4234), and polytrauma with Injury Severity Score (ISS) >16 (n = 1596). No comparison of aspirin versus LMWH within the 11 subpopulations for the 5 outcomes reached the corrected threshold for statistical significance of P < 0.001. However, 5 comparisons of aspirin versus LMWH were less than the conventional P -value of 0.05. Specifically, the aspirin group demonstrated lower mortality in patients with a head injury (difference, −3.2%; 95% CI −6.1% to −0.3%; P = 0.03) or a spine injury (difference, −6.0%; 95% CI −11.7% to −0.3%; P = 0.04) than the LMWH group. The LMWH group demonstrated a lower rate of distal DVTs for patients with a head injury (difference, 4.4%; 95% CI, 0.8% to 8.1%; P = 0.02), thoracic injury (difference, 1.5%; 95% CI, 0.0% to 2.9%; P = 0.04) or with ISS >16 (difference, 1.7%; 95% CI, 0.2% to 3.3; P = 0.03) than the aspirin group. CONCLUSIONS: Within 11 high-risk or fracture location-specific subpopulations, there were no statistically significant differences between aspirin and LMWH in the 90-day rates of all-cause mortality, nonfatal PE, proximal DVT, distal DVT, or bleeding complications at a threshold corrected for multiple comparisons ( P < 0.001). LEVEL OF EVIDENCE: Therapeutic Level II. See Instructions for Authors for a complete description of levels of evidence.
- Open Access
- 29 September 2025
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 13 (4) , 49
Balancing Costs and Clinical Outcomes: A Cost-Effectiveness Study of PICC Types Across Chinese Healthcare Settings
Long-term intravenous therapies often necessitate the use of peripherally inserted central catheters (PICCs). Antimicrobial-coated PICCs have been introduced to minimize central line-associated bloodstream infections (CLABSIs). A decision-analytic cost-effectiveness model was developed from a societal perspective, utilizing real-world data concerning PICC-related complications and costs from Class 3A hospitals and community hospital settings in China. The analysis compared the quality-adjusted life years (QALYs) for patients receiving antimicrobial-coated PICCs versus standard PICCs, with catheter-associated costs included. Incremental cost-effectiveness ratios (ICERs) were calculated in Chinese Yuan (CNY) per QALY gained. Patients with antimicrobial-coated PICCs experienced slightly fewer complication-related events, leading to significantly lower costs for managing complications. In the Class 3A hospital setting, the average total cost per patient was lower with antimicrobial-coated PICCs (CNY 62,800) compared to standard PICCs (CNY 102,900), primarily due to the reduced expenses for treating CLABSIs and related unknown fever. The ICER demonstrated that the coated PICC was the strongest option, showing a negative ICER (cost-saving of approximately CNY 4 million per QALY gained in the base-case Class 3A hospital scenario). In community hospital care scenarios, the cost advantage of antimicrobial-coated PICCs remained. Thus, the antimicrobial-coated PICC strategy was cost-saving, providing equal or improved health outcomes at lower costs in China’s medical center and community hospitals, making it a more efficient choice for long-term vascular access.
- 29 September 2025
- Published by MDPI AG in Journal of Market Access & Health Policy
- Vol. 13 (4) , 49
Open AccessBalancing Costs and Clinical Outcomes: A Cost-Effectiveness Study of PICC Types Across Chinese Healthcare Settings
Long-term intravenous therapies often necessitate the use of peripherally inserted central catheters (PICCs). Antimicrobial-coated PICCs have been introduced to minimize central line-associated bloodstream infections (CLABSIs). A decision-analytic cost-effectiveness model was developed from a societal perspective, utilizing real-world data concerning PICC-related complications and costs from Class 3A hospitals and community hospital settings in China. The analysis compared the quality-adjusted life years (QALYs) for patients receiving antimicrobial-coated PICCs versus standard PICCs, with catheter-associated costs included. Incremental cost-effectiveness ratios (ICERs) were calculated in Chinese Yuan (CNY) per QALY gained. Patients with antimicrobial-coated PICCs experienced slightly fewer complication-related events, leading to significantly lower costs for managing complications. In the Class 3A hospital setting, the average total cost per patient was lower with antimicrobial-coated PICCs (CNY 62,800) compared to standard PICCs (CNY 102,900), primarily due to the reduced expenses for treating CLABSIs and related unknown fever. The ICER demonstrated that the coated PICC was the strongest option, showing a negative ICER (cost-saving of approximately CNY 4 million per QALY gained in the base-case Class 3A hospital scenario). In community hospital care scenarios, the cost advantage of antimicrobial-coated PICCs remained. Thus, the antimicrobial-coated PICC strategy was cost-saving, providing equal or improved health outcomes at lower costs in China’s medical center and community hospitals, making it a more efficient choice for long-term vascular access.
- Open Access
- 7 April 2025
- Published by MDPI AG in Preprints.org
Balancing Costs and Clinical Outcomes: A Cost-effectiveness Study of PICC Types Across Chinese Healthcare Settings
Long-term intravenous therapies often necessitate the use of peripherally inserted central catheters (PICCs), and antimicrobial-coated PICCs have been introduced to minimize catheter-related infections. A decision-analytic cost-effectiveness model was developed from a societal perspective utilizing real-world data concerning PICC-related complications and costs from Class 3A hospitals and community hospital settings in China. The analysis compared the quality-adjusted life years (QALYs) for patients receiving antimicrobial-coated PICCs versus standard PICCs, with catheter-associated costs included. Incremental cost-effectiveness ratios (ICERs) were calculated in Chinese Yuan (¥) per QALY gained.Patients with antimicrobial-coated PICCs experienced slightly fewer complication-related events, leading to significantly lower costs for managing complications. In the Class 3A hospital setting, the average total cost per patient was lower with antimicrobial-coated PICCs (¥62,800) compared to standard PICCs (¥102,900), primarily due to reduced expenses for treating CLABSI and related unknown fever. The ICER demonstrated that the coated PICC was the dominant option, showing a negative ICER (cost-saving of approximately ¥4 million per QALY gained in the base-case Class 3A hospital scenario). In community hospital care scenarios, the cost advantage of antimicrobial-coated PICCs remained. Thus, the antimicrobial-coated PICC strategy was cost-saving, providing equal or improved health outcomes at lower costs in China's medical center and community hospital settings, making it a more efficient choice for long-term vascular access.
- 7 April 2025
- Published by MDPI AG in Preprints.org
Open AccessBalancing Costs and Clinical Outcomes: A Cost-effectiveness Study of PICC Types Across Chinese Healthcare Settings
Long-term intravenous therapies often necessitate the use of peripherally inserted central catheters (PICCs), and antimicrobial-coated PICCs have been introduced to minimize catheter-related infections. A decision-analytic cost-effectiveness model was developed from a societal perspective utilizing real-world data concerning PICC-related complications and costs from Class 3A hospitals and community hospital settings in China. The analysis compared the quality-adjusted life years (QALYs) for patients receiving antimicrobial-coated PICCs versus standard PICCs, with catheter-associated costs included. Incremental cost-effectiveness ratios (ICERs) were calculated in Chinese Yuan (¥) per QALY gained.Patients with antimicrobial-coated PICCs experienced slightly fewer complication-related events, leading to significantly lower costs for managing complications. In the Class 3A hospital setting, the average total cost per patient was lower with antimicrobial-coated PICCs (¥62,800) compared to standard PICCs (¥102,900), primarily due to reduced expenses for treating CLABSI and related unknown fever. The ICER demonstrated that the coated PICC was the dominant option, showing a negative ICER (cost-saving of approximately ¥4 million per QALY gained in the base-case Class 3A hospital scenario). In community hospital care scenarios, the cost advantage of antimicrobial-coated PICCs remained. Thus, the antimicrobial-coated PICC strategy was cost-saving, providing equal or improved health outcomes at lower costs in China's medical center and community hospital settings, making it a more efficient choice for long-term vascular access.
- Open Access
- 4 March 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (3) , 373
Evaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard Peripheral Insertion Central Catheters in Patients with Hematologic Disease: A Health Economic Analysis
Background/Objectives: This study was conducted to assess the cost-effectiveness of chlorhexidine-coated (AGBA) peripheral insertion central catheters (PICCs) versus standard PICCs for managing catheter-related complications among patients with hematologic disease. Methods: A decision tree health economic model was developed, incorporating quality-adjusted life years (QALYs) derived from the literature, as well as complication rates and per-patient costs from a randomized controlled trial. The base case incremental cost-effectiveness ratio (ICER) was assessed against established willingness to pay (WTP) thresholds. One-way sensitivity analyses were conducted to address assumptions and uncertainties. Results: The mean healthcare cost per patient of standard PICCs was RMB 21,987.32 (USD 3242.82, at an average exchange rate of RMB 678.03 = USD 100), affecting 0.68 QALYs in 90 days. The mean healthcare cost per patient of AGBA PICCs was RMB 19,696.23 (USD 2904.92), affecting 0.73 QALYs in 90 days, thus resulting in a saving of RMB 2291.10 (USD 428.44). After the model simulation, standard PICCs resulted in a reduction of 0.05 QALYs. The ICER for AGBA PICCs compared with standard PICCs was consistently centered at RMB 4271.31 (USD 629.96). Conclusions: one-way sensitivity analyses of cost-effectiveness versus WTP confirmed the robustness of the model across various parameter changes, indicating that AGBA PICCs could provide significant healthcare savings over a 1-year period when adopted in routine chemotherapy treatment for patients with hematologic disease.
- 4 March 2025
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 22 (3) , 373
Open AccessEvaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard Peripheral Insertion Central Catheters in Patients with Hematologic Disease: A Health Economic Analysis
Background/Objectives: This study was conducted to assess the cost-effectiveness of chlorhexidine-coated (AGBA) peripheral insertion central catheters (PICCs) versus standard PICCs for managing catheter-related complications among patients with hematologic disease. Methods: A decision tree health economic model was developed, incorporating quality-adjusted life years (QALYs) derived from the literature, as well as complication rates and per-patient costs from a randomized controlled trial. The base case incremental cost-effectiveness ratio (ICER) was assessed against established willingness to pay (WTP) thresholds. One-way sensitivity analyses were conducted to address assumptions and uncertainties. Results: The mean healthcare cost per patient of standard PICCs was RMB 21,987.32 (USD 3242.82, at an average exchange rate of RMB 678.03 = USD 100), affecting 0.68 QALYs in 90 days. The mean healthcare cost per patient of AGBA PICCs was RMB 19,696.23 (USD 2904.92), affecting 0.73 QALYs in 90 days, thus resulting in a saving of RMB 2291.10 (USD 428.44). After the model simulation, standard PICCs resulted in a reduction of 0.05 QALYs. The ICER for AGBA PICCs compared with standard PICCs was consistently centered at RMB 4271.31 (USD 629.96). Conclusions: one-way sensitivity analyses of cost-effectiveness versus WTP confirmed the robustness of the model across various parameter changes, indicating that AGBA PICCs could provide significant healthcare savings over a 1-year period when adopted in routine chemotherapy treatment for patients with hematologic disease.
- Open Access
- 10 January 2025
- Published by MDPI AG in Preprints.org
Evaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard PICCs in Hematology Patients: A Health-Economic Analysis
This study assesses the cost-effectiveness of using chlorhexidine-coated peripheral insertion central catheters (AGBA PICC) versus the standard peripheral insertion central catheters (the standard PICC) in managing catheter-related complications among hematology patients. A decision-tree health-economic model was developed, incorporating quality-adjusted life years (QALY) derived from literature, as well as complication rates and per-patient costs from a randomized controlled trial. The base case incremental cost-effectiveness ratio (ICER) was assessed against established willingness-to-pay thresholds. One-way sensitivity analyses addressed assumptions and uncertainties. The mean healthcare cost per patient of the standard PICC is RMB 21,987.32 (USD 3,242.82, at an average exchange rate of ¥678.03 = $100), affecting 0.68 QALYs in 90 days, and AGBA PICC is RMB 19,696.23 (USD 2,904.92), affecting 0.73 QALYs in 90 days, thus resulting in incremental costs of RMB 2,291.10 (USD 428.44). After the model’s simulation, the standard PICC gains -0.05 QALYs. The Incremental Cost-Effectiveness Ratio (ICER) for AGBA PICCs compared to standard PICCs is consistently centered at RMB 4,271.31 (USD 629.96). One-way sensitivity analyses of effectiveness and cost versus willingness to pay (WTP) confirmed the robustness of the model across various parameter changes, indicating that chlorhexidine-coated peripheral insertion central catheters could provide significant healthcare savings over a one-year period when adopted in routine chemotherapy treatment for hematology patients.
- 10 January 2025
- Published by MDPI AG in Preprints.org
Open AccessEvaluating the Cost-Effectiveness of Chlorhexidine-Coated vs. Standard PICCs in Hematology Patients: A Health-Economic Analysis
This study assesses the cost-effectiveness of using chlorhexidine-coated peripheral insertion central catheters (AGBA PICC) versus the standard peripheral insertion central catheters (the standard PICC) in managing catheter-related complications among hematology patients. A decision-tree health-economic model was developed, incorporating quality-adjusted life years (QALY) derived from literature, as well as complication rates and per-patient costs from a randomized controlled trial. The base case incremental cost-effectiveness ratio (ICER) was assessed against established willingness-to-pay thresholds. One-way sensitivity analyses addressed assumptions and uncertainties. The mean healthcare cost per patient of the standard PICC is RMB 21,987.32 (USD 3,242.82, at an average exchange rate of ¥678.03 = $100), affecting 0.68 QALYs in 90 days, and AGBA PICC is RMB 19,696.23 (USD 2,904.92), affecting 0.73 QALYs in 90 days, thus resulting in incremental costs of RMB 2,291.10 (USD 428.44). After the model’s simulation, the standard PICC gains -0.05 QALYs. The Incremental Cost-Effectiveness Ratio (ICER) for AGBA PICCs compared to standard PICCs is consistently centered at RMB 4,271.31 (USD 629.96). One-way sensitivity analyses of effectiveness and cost versus willingness to pay (WTP) confirmed the robustness of the model across various parameter changes, indicating that chlorhexidine-coated peripheral insertion central catheters could provide significant healthcare savings over a one-year period when adopted in routine chemotherapy treatment for hematology patients.
- 25 November 2024
- Published by Wolters Kluwer Health in OTA International
- Vol. 7 (4) , e348
Predicting deep infection in pilon and tibial plateau fractures: a secondary analysis of the VANCO and OXYGEN trials
Objectives: To develop and validate a prediction model for a deep surgical site infection (SSI) after fixation of a tibial plateau or pilon fracture. Design: Pooled data from 2 randomized trials (VANCO and OXYGEN). Setting: Fifty-two US trauma centers. Patients: In total, 1847 adult patients with operatively treated tibial plateau or pilon fractures who met criteria for a high risk of infection. Intervention: We considered 13 baseline patient characteristics and developed and externally validated prediction models using 3 approaches (logistic regression, stepwise elimination, and machine learning). Main Outcomes and Measures: The primary prediction model outcome was a deep SSI requiring operative debridement within 182 days of definitive fixation. Our primary prognostic performance metric for evaluating the models was area under the receiver operating characteristic curve (AUC) with clinical utility set at 0.7. Results: Deep SSI occurred in 75 VANCO patients (8%) and in 56 OXYGEN patients (6%). The machine learning model for VANCO (AUC = 0.65) and stepwise elimination model for OXYGEN (AUC = 0.62) had the highest internal validation AUCs. However, none of the external validation AUCs exceeded 0.64 (range, 0.58 to 0.64). Conclusions: The predictive models did not reach the prespecified clinical utility threshold. Our models' inability to distinguish high-risk from low-risk patients is likely due to strict eligibility criteria and, therefore, homogeneous patient populations.
- 25 November 2024
- Published by Wolters Kluwer Health in OTA International
- Vol. 7 (4) , e348
Predicting deep infection in pilon and tibial plateau fractures: a secondary analysis of the VANCO and OXYGEN trials
Objectives: To develop and validate a prediction model for a deep surgical site infection (SSI) after fixation of a tibial plateau or pilon fracture. Design: Pooled data from 2 randomized trials (VANCO and OXYGEN). Setting: Fifty-two US trauma centers. Patients: In total, 1847 adult patients with operatively treated tibial plateau or pilon fractures who met criteria for a high risk of infection. Intervention: We considered 13 baseline patient characteristics and developed and externally validated prediction models using 3 approaches (logistic regression, stepwise elimination, and machine learning). Main Outcomes and Measures: The primary prediction model outcome was a deep SSI requiring operative debridement within 182 days of definitive fixation. Our primary prognostic performance metric for evaluating the models was area under the receiver operating characteristic curve (AUC) with clinical utility set at 0.7. Results: Deep SSI occurred in 75 VANCO patients (8%) and in 56 OXYGEN patients (6%). The machine learning model for VANCO (AUC = 0.65) and stepwise elimination model for OXYGEN (AUC = 0.62) had the highest internal validation AUCs. However, none of the external validation AUCs exceeded 0.64 (range, 0.58 to 0.64). Conclusions: The predictive models did not reach the prespecified clinical utility threshold. Our models' inability to distinguish high-risk from low-risk patients is likely due to strict eligibility criteria and, therefore, homogeneous patient populations.
- 11 November 2024
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 39 (2) , 75-81
Are Drains Associated With Infection After Operative Fixation of High-Risk Tibial Plateau and Pilon Fractures?
OBJECTIVES: To determine the association between closed suction drainage and postoperative infection in patients with tibial plateau or pilon fractures. Secondarily, this study assessed if intrawound vancomycin powder modified the association of closed surgical drains with infection. METHODS: Design: Secondary analysis of the Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial (VANCO) trial. Setting: 36 academic trauma centers. Patient Selection Criteria: All patients with high-risk tibia fractures (OTA/AO classification 41B/C or 43B/C) from the VANCO trial were considered. Closed suction drains were placed based on the treating surgeon’s discretion. Patients were randomly assigned to received 1-gram intrawound vancomycin powder in the surgical wound at definitive fixation or the standard infection prevention protocol at each center. Outcome Measures and Comparisons: Deep surgical site infection (SSI) within 6 months. Comparisons were made between patients treated with and without drains. Subgroup analysis also examined the effect of drains in patients with and without intrawound vancomycin powder. RESULTS: Of the 978 study patients, 197 (20%) were treated with drains. Deep infection rates did not significantly differ between patients with or without surgical drains (8% versus 8%, p=0.88). However, intrawound vancomycin powder significantly modified the association of surgical drains on deep SSI (interaction p=0.048). Specifically, patients with drains but no vancomycin powder had the highest deep infection rate (13%; 95% CI, 6% to 19%). When vancomycin powder was used in addition to a drain, deep SSI rates were reduced by 10% (95% CI, 2% to 17%, p=0.01). CONCLUSIONS: This study suggests that closed suction drains after operative fixation of high-risk tibia fractures may not be associated with deep infection in general. However, a secondary analysis raises the possibility that drains are associated with reduced deep infection rates if topical vancomycin powder is used but associated with increased infection rates if vancomycin powder is not used. LEVEL OF EVIDENCE: Level III
- 11 November 2024
- Published by Wolters Kluwer Health in Journal of Orthopaedic Trauma
- Vol. 39 (2) , 75-81
Are Drains Associated With Infection After Operative Fixation of High-Risk Tibial Plateau and Pilon Fractures?
OBJECTIVES: To determine the association between closed suction drainage and postoperative infection in patients with tibial plateau or pilon fractures. Secondarily, this study assessed if intrawound vancomycin powder modified the association of closed surgical drains with infection. METHODS: Design: Secondary analysis of the Effect of Intrawound Vancomycin Powder in Operatively Treated High-risk Tibia Fractures: A Randomized Clinical Trial (VANCO) trial. Setting: 36 academic trauma centers. Patient Selection Criteria: All patients with high-risk tibia fractures (OTA/AO classification 41B/C or 43B/C) from the VANCO trial were considered. Closed suction drains were placed based on the treating surgeon’s discretion. Patients were randomly assigned to received 1-gram intrawound vancomycin powder in the surgical wound at definitive fixation or the standard infection prevention protocol at each center. Outcome Measures and Comparisons: Deep surgical site infection (SSI) within 6 months. Comparisons were made between patients treated with and without drains. Subgroup analysis also examined the effect of drains in patients with and without intrawound vancomycin powder. RESULTS: Of the 978 study patients, 197 (20%) were treated with drains. Deep infection rates did not significantly differ between patients with or without surgical drains (8% versus 8%, p=0.88). However, intrawound vancomycin powder significantly modified the association of surgical drains on deep SSI (interaction p=0.048). Specifically, patients with drains but no vancomycin powder had the highest deep infection rate (13%; 95% CI, 6% to 19%). When vancomycin powder was used in addition to a drain, deep SSI rates were reduced by 10% (95% CI, 2% to 17%, p=0.01). CONCLUSIONS: This study suggests that closed suction drains after operative fixation of high-risk tibia fractures may not be associated with deep infection in general. However, a secondary analysis raises the possibility that drains are associated with reduced deep infection rates if topical vancomycin powder is used but associated with increased infection rates if vancomycin powder is not used. LEVEL OF EVIDENCE: Level III